Study guide

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols

Key Takeaways Explain This Topic AI

Clinical grading of dehydration severity relies on objective physiological signs: Mild (<5% weight loss: normal capillary refill time, moist mucous membranes, normal skin turgor), Moderate (5–9% weight loss: delayed CRT 2–3s, dry mucous membranes, sunken eyes/fontanelle, loss of skin turgor/slow recoil), and Severe (≥10% weight loss: prolonged CRT ≥3s, cool mottled peripheries, lethargy or coma, deep acidotic breathing, tachycardia, hypotension).

Oral Rehydration Therapy (ORT) with low-osmolarity ORS (245 mOsm/L, 75 mEq/L Na+) is the first-line intervention for mild-to-moderate dehydration, administered at 50–100 mL/kg over 4 hours plus replacement of ongoing losses (10 mL/kg per diarrheal stool, 2–5 mL/kg per vomit), with uninterrupted continuation of breastfeeding and early re-feeding.

IV fluids are indicated for shock, impaired consciousness or an unsafe gastrointestinal route, and for persistent oral/NG rehydration failure. High stool output requires adequate loss replacement and reassessment; it does not alone preclude enteral therapy.

Emergency fluid resuscitation in severe dehydration with shock mandates rapid administration of 10 to 20 mL/kg isotonic balanced crystalloid (Plasmalyte 148 or Ringer's lactate) or 0.9% normal saline over 10–20 minutes, followed by deficit replacement over 24 hours (or 48 hours in hypernatremia) plus Holliday-Segar maintenance fluids, withholding added potassium until adequate renal output is confirmed.

Pharmacological adjunctive therapy is strictly limited: routine antibiotics are avoided, antimotility agents (loperamide) are strictly contraindicated due to risk of paralytic ileus and toxic megacolon, while a single oral dose of ondansetron (0.15 mg/kg) reduces emesis and hospital admission, and zinc use follows the nutritional setting and applicable guidance rather than routine European prescribing.

Last updated: November 2026

Acute Gastroenteritis and Dehydration: Severity Assessment, Oral Rehydration Therapy, and Intravenous Fluid Protocols

Acute gastroenteritis (AGE) remains one of the leading causes of paediatric morbidity, emergency department consultations, and hospital admissions globally and across Europe. AGE is defined as a diarrheal illness of rapid onset, with or without vomiting, fever, or abdominal pain, typically lasting less than 7 to 14 days. The primary pathophysiological consequence and principal driver of mortality in acute gastroenteritis is dehydration and electrolyte disturbance resulting from the loss of water, sodium, potassium, and bicarbonate in watery stools and emesis. Mastering the clinical evaluation of fluid volume depletion, the execution of Oral Rehydration Therapy (ORT), and the precise calculation of intravenous resuscitation and maintenance fluids is a core competency for the European Board of Paediatrics (EBP-EAP) examination.

Etiology and Pathophysiological Mechanisms

In European and industrialized settings, viruses account for over 70% to 80% of acute gastroenteritis episodes:

Rotavirus: Historically the leading cause of severe dehydrating diarrhea in young children; incidence has declined markedly following the introduction of live-attenuated oral rotavirus vaccines (Rotarix, RotaTeq). Rotavirus infects mature enterocytes of the mid- and upper small-intestinal villi, causing blunting of villi, loss of brush-border disaccharidases (inducing secondary transient lactose malabsorption), and secretion of the viral enterotoxin NSP4 , which triggers phospholipase C-dependent intracellular calcium release and active chloride secretion.

Norovirus: Currently the predominant cause of both sporadic gastroenteritis and institutional outbreaks across all age groups. It exhibits high infectivity, environmental stability, and rapid genetic evolution.

Enteric Adenoviruses (Serotypes 40/41), Astroviruses, and Sapoviruses: Common viral causes producing mild-to-moderate watery diarrhea.

Bacterial Pathogens: (10–20% of cases) Include Campylobacter jejuni (most common bacterial cause in Europe, often associated with poultry ingestion), Salmonella enterica (non-typhoidal), Shigella sonnei , and Yersinia enterocolitica . Bacterial enteropathogens invade mucosal enterocytes or produce cytotoxic enterotoxins, often presenting with high fever, severe abdominal cramps, tenesmus, and dysentery (macroscopic blood, mucus, and leukocytes in stool).

Shiga Toxin-producing Escherichia coli (STEC / EHEC, e.g., O157:H7): Causes hemorrhagic colitis and carries a high risk (10–15%) of precipitating Hemolytic Uremic Syndrome (HUS) , characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury.

Clinical Assessment and Severity Grading of Dehydration

Accurate assessment of dehydration severity dictates the clinical setting (outpatient vs inpatient) and the route of rehydration (oral vs enteral via nasogastric tube vs intravenous). Clinical dehydration assessment correlates historical features, physical examination signs, and percentage of acute body weight loss. [Clinical Signs of Dehydration]

  • |
  • +------------------------------------+------------------------------------+
  • | | |
  • [Mild (<5%)] [Moderate (5–9%)] [Severe (≥10%)]
  • Normal CRT (<2s) - Delayed CRT (2–3s) - Prolonged CRT (≥3s)
  • Moist mucous membranes - Dry mucous membranes - Parched/cracked mucosa
  • Normal skin turgor - Decreased turgor (slow recoil) - Skin tenting (>2s)
  • Normal eyes & fontanelle - Sunken eyes & fontanelle - Deeply sunken eyes
  • Alert, thirsty - Irritable, restless - Lethargic, comatose
  • Normal pulses & BP - Mild tachycardia - Thready pulse, shock
  • Clinical Dehydration Classification Scheme

Assessment Parameter Mild Dehydration (<5% Weight Loss) Moderate Dehydration (5–9% Weight Loss) Severe Dehydration (≥10% Weight Loss)

Mental / Neurological Status Alert, interactive, normal responsiveness Irritable, restless, thirsty, easily unsettled Lethargic, stuporous, floppiness, comatose

Capillary Refill Time (CRT) Normal (<2 seconds) Prolonged (2 to 3 seconds) Markedly prolonged (≥3 seconds, cool mottled limbs)

Skin Turgor (Skin Pinch) Normal, instantaneous skin snapback Reduced, skin fold retracts slowly (<2 seconds) Markedly reduced; skin tenting (retracts >2 seconds)

Mucous Membranes Moist lips and tongue Dry lips, sticky oral mucosa Parched, cracked lips; dry, coated tongue

Eyes & Tear Production Normal tears, normal orbital contour Sunken eyes, markedly decreased tearing Deeply sunken eyes, absent tears, dry conjunctivae

Anterior Fontanelle Normal, flat Sunken below the level of the skull bones Deeply sunken, prominent cranial bones

Heart Rate & Peripheral Pulses Normal heart rate, strong peripheral pulses Tachycardia, normal to slightly reduced pulse volume Marked tachycardia, weak, thready, or impalpable pulses

Respiratory Pattern Normal rate and effort Tachypnea, normal depth Deep, rapid, sighing respirations (Kussmaul breathing)

Blood Pressure Normal for age Normal (compensated) Hypotension (decompensated shock; late, ominous sign)

Urine Output Normal or slightly concentrated Reduced (oliguria, dark concentrated urine) Anuria or marked oliguria (<0.5 mL/kg/h)

Important

The three most predictive individual physical examination signs for diagnosing dehydration in young children are prolonged capillary refill time , abnormal skin turgor (delayed recoil) , and abnormal respiratory pattern (acidotic tachypnea) . Relying on a single sign such as dry mouth or absence of tears in an infant who is crying actively is unreliable.

Oral Rehydration Therapy (ORT) Protocol

Oral Rehydration Therapy (ORT) is the gold standard first-line treatment recommended by ESPGHAN, WHO, and AAP for infants and children with mild-to-moderate dehydration from acute gastroenteritis. ORT exploits the intact sodium-glucose cotransporter 1 ( SGLT1 ) in the brush border of intestinal enterocytes: two sodium ions are cotransported with each glucose molecule, creating an osmotic gradient that drives passive water reabsorption across the luminal membrane even in the presence of severe secretory diarrhea.

Low-Osmolarity ORS Composition

Older WHO formulations (total osmolarity 311 mOsm/L, sodium 90 mmol/L) were associated with hypernatremia and prolonged diarrheal purging. Modern evidence supports low-osmolarity ORS (total osmolarity 245 mOsm/L), which reduces stool output by 20%, decreases vomiting by 30%, and lowers the need for rescue intravenous hydration by 33%.

  • Sodium: 75 mmol/L (mEq/L) — ESPGHAN European formulation recommends 60 mmol/L (range 50–60)
  • Glucose: 75 mmol/L (13.5 g/L)
  • Potassium: 20 mmol/L
  • Chloride: 65 mmol/L
  • Citrate: 10 mmol/L
  • Total Osmolarity: 245 mOsm/L
  • Clinical ORT Administration Regimen

Rehydration Phase (First 4 Hours):

Mild Dehydration (<5%): Administer 50 mL/kg of low-osmolarity ORS orally over 4 hours .

Moderate Dehydration (5–9%): Administer 100 mL/kg of low-osmolarity ORS orally over 4 hours .

Technique of Administration: Give small, frequent aliquots—typically 5 mL (one teaspoon or syringe) every 1 to 2 minutes . Rapid drinking from a bottle or cup distends the stomach and triggers the emetic reflex. If the infant vomits, wait 5 to 10 minutes , then resume administration at a slower rate (e.g., 2 to 3 mL every 2 minutes).

Replacement of Ongoing Fluid Losses:

Replace each loose, watery stool with 10 mL/kg of ORS.

Replace each episode of significant vomiting with 2 to 5 mL/kg of ORS.

Nasogastric (NG) Tube Rehydration: If oral administration fails due to persistent refusal or exhaustion, enteral rehydration via a fine-bore nasogastric tube at 15 to 25 mL/kg/h using an infusion pump is safer and more effective than proceeding directly to peripheral intravenous cannulation.

Maintenance and Early Nutritional Re-feeding:

Breastfeeding should never be interrupted during ORT; breast milk provides protective antibodies, lactoferrin, and epidermal growth factor that accelerate mucosal repair.

In formula-fed and older children, age-appropriate solid feeding should be resumed immediately after the 4-hour rehydration phase is complete .

Diluting formula or using restrictive diets (such as the traditional BRAT diet: bananas, rice, applesauce, toast) is expressly discouraged , as it leads to prolonged hypocaloric malnutrition and delays enterocyte brush-border regeneration.

Indications and Protocols for Intravenous Fluid Resuscitation

Intravenous fluid therapy is indicated when enteral rehydration is either impossible, unsafe, or failing to keep pace with pathological fluid losses.

Indications for Intravenous Rehydration

Hypovolemic Shock: Decompensated (hypotension) or compensated shock (CRT ≥3 seconds, tachycardia, cool extremities, thready pulses).

Severe Dehydration (≥10%): Altered level of consciousness (lethargy, stupor, coma).

Persistent Emesis: Failure of supervised oral and, when safe, nasogastric ORS; consider single-dose ondansetron in appropriate children.

Failure of Enteral Therapy: Worsening dehydration or persistent inability to tolerate fluids via oral and nasogastric routes.

Paralytic Ileus, Abdominal Distension, or Acute Surgical Abdomen: Suspicion of intussusception, appendicitis, or toxic megacolon.

Severe Malabsorption or High Output: IV replacement may be needed when losses exceed tolerated enteral replacement; a high stool rate alone does not rule out ORT.

  • Phases of Intravenous Fluid Therapy [Intravenous Fluid Resuscitation Protocol]
  • |
  • +---------------------------------+---------------------------------+
  • | |
  • [Phase 1: Resuscitation] [Phase 2: Deficit + Maintenance + Ongoing Losses]
  • 10 to 20 mL/kg Isotonic Balanced Crystalloid - Calculate Holliday-Segar Maintenance
  • (Plasmalyte 148 / Ringer's Lactate / 0.9% Saline) - Calculate Water Deficit (% Dehydration)
  • Infuse over 10 to 20 minutes (push in severe shock) - Replace deficit over 24h (48h if hypernatremic)
  • Reassess vitals, CRT, and perfusion - Add 20 mmol/L KCl ONLY AFTER urine output established
  • Repeat bolus if shock persists (up to 40–60 mL/kg)
  • Phase 1: Rapid Restoration of Intravascular Volume (Emergency Bolus)

In the presence of shock or critical hypoperfusion, the immediate objective is expansion of the effective circulating arterial volume to preserve cerebral, coronary, and renal microperfusion.

Fluid Type: Isotonic balanced crystalloid (e.g., Plasmalyte 148, Hartmann's solution, or Ringer's lactate) or 0.9% Sodium Chloride (isotonic saline) . Balanced crystalloids are preferred in European guidelines to avoid hyperchloremic metabolic acidosis.

Volume & Rate: 10 to 20 mL/kg administered as an intravenous or intraosseous bolus over 10 to 20 minutes .

Immediate Reassessment: Evaluate heart rate, peripheral pulses, capillary refill time, and level of consciousness. If signs of hypoperfusion persist, repeat the 10 to 20 mL/kg bolus up to a cumulative volume of 40 to 60 mL/kg , while actively monitoring for signs of fluid overload (hepatomegaly, pulmonary crackles, gallop rhythm).

Phase 2: Deficit Replacement and Ongoing Maintenance Fluids

Once circulation is stable, prescribe remaining deficit + maintenance + ongoing losses . Replace continuing gastrointestinal losses separately, preferably using measured volumes, and reassess the fluid balance.

1. Calculation of Fluid Deficit: Deficit (mL) = % Dehydration × Body Weight (kg) × 10 \text{Deficit (mL)} = \% \text{ Dehydration} \times \text{Body Weight (kg)} \times 10 Deficit (mL) = % Dehydration × Body Weight (kg) × 10 Example: A 10 kg child with 8% dehydration has a total fluid deficit of 8 × 10 × 10 = 800 mL 8 \times 10 \times 10 = 800\text{ mL} 8 × 10 × 10 = 800 mL . Any resuscitation bolus administered during Phase 1 is subtracted from this deficit.

2. Calculation of Daily Maintenance Fluids (Holliday-Segar Formula):

First 10 kg of body weight: 100 mL/kg/day 100\text{ mL/kg/day} 100 mL/kg/day

Second 10 kg (11 to 20 kg): Add 50 mL/kg/day 50\text{ mL/kg/day} 50 mL/kg/day for each kilogram between 11 and 20 kg

Each kilogram above 20 kg: Add 20 mL/kg/day 20\text{ mL/kg/day} 20 mL/kg/day for each kilogram > 20 kg >20\text{ kg} > 20 kg Hourly Maintenance Rule (4-2-1 Rule): 4 mL/kg/h 4\text{ mL/kg/h} 4 mL/kg/h for the first 10 kg, 2 mL/kg/h 2\text{ mL/kg/h} 2 mL/kg/h for 11–20 kg, and 1 mL/kg/h 1\text{ mL/kg/h} 1 mL/kg/h for each kg > 20 kg >20\text{ kg} > 20 kg .

3. Fluid Composition and Administration Schedule:

In isonatremic (Na 135–145 mmol/L) or hyponatremic (Na <135 mmol/L) dehydration: Replace the deficit plus maintenance over 24 hours (typically half administered over the first 8 hours, and the remaining half over the subsequent 16 hours) using an isotonic maintenance solution containing glucose (e.g., 0.9% NaCl with 5% Dextrose, or balanced paediatric maintenance solution).

Potassium Replacement: Add 20 to 40 mmol/L Potassium Chloride (KCl) to maintenance fluids strictly after the child has voided urine spontaneously and adequate renal function is confirmed. Adding KCl to intravenous fluids in an anuric child risks lethal hyperkalemia and ventricular arrhythmias.

Warning

Hypotonic Solutions Danger: Routine maintenance should use isotonic fluid: very hypotonic solutions (e.g., 0.18% or 0.2% NaCl with glucose) can cause hospital-acquired hyponatremic encephalopathy during non-osmotic ADH release. Specific electrolyte disorders may require a tailored fluid prescription with specialist advice and monitoring.

Hypernatremic Dehydration Management

Hypernatremic dehydration (serum sodium >145 to 150 mmol/L ) occurs in 5% to 10% of infants with acute gastroenteritis, typically when water losses exceed sodium losses (e.g., high-evaporative fever, tachypnea, ingestion of improperly concentrated formula, or high-solute solutions).

Clinical Presentation: Intracellular water is drawn into the hypertonic extracellular space, preserving intravascular volume and blood pressure. Consequently, classical signs of dehydration appear deceptively delayed. Infants exhibit doughy or velvety skin turgor , a high-pitched shrill cry, extreme lethargy alternating with hyperirritability, hypertonia, hyperreflexia, and fever.

Pathophysiology of Cerebral Injury: Hypertonicity causes brain cell dehydration and shrinkage, pulling cerebral bridging veins taut and risking subdural and subarachnoid hemorrhages, as well as dural sinus thrombosis. Over 24 to 48 hours, brain cells synthesize idiogenic intracellular osmoles (taurine, myo-inositol, betaine) to restore intracellular brain volume.

Rehydration Strategy and Sodium Correction Rate: If intravascular volume is depleted, administer 10 to 20 mL/kg isotonic crystalloid to restore perfusion. Once stabilized, replace the remaining deficit slowly over about 48 hours , initially with 0.9% NaCl and 5% glucose plus maintenance and ongoing-loss replacement. Check sodium frequently; adjust with specialist advice if correction is too fast or inadequate. 0.45% saline is hypotonic , not interchangeable initial therapy.

Safe Rate of Sodium Reduction: Serum sodium must not decrease by more than 0.5 mmol/L per hour , with a maximum decline of 10 to 12 mmol/L in 24 hours . Rapid reduction of extracellular tonicity causes rapid water influx into brain cells containing high idiogenic osmoles, triggering catastrophic cerebral edema, intractable seizures, and uncal herniation .

  • Pharmacological and Adjunctive Interventions
  • Oral Ondansetron

A single oral dose of ondansetron (selective 5 - H T 3 5\text{-}HT_3 5 - H T 3 ​ receptor antagonist) is recommended in children aged 6 months to 10 years with mild-to-moderate dehydration who have persistent vomiting that hampers ORT.

Dosing Protocol: Weight-based single oral dose: 8 to 15 kg: 2 mg ; 15 to 30 kg: 4 mg ; >30 kg: 8 mg (or approximately 0.15 mg/kg ).

Clinical Benefits: Significantly reduces persistent emesis, increases the success rate of ORT, halves the need for intravenous fluid administration, and decreases emergency department admission rates.

Adverse Effects: May increase diarrhoea transiently; this is usually mild and self-limited, lasting less than 48 hours.

Caution

Strict Contraindication of Antimotility Agents: Antimotility agents such as loperamide , diphenoxylate-atropine, and tincture of opium are strictly contraindicated in infants and children. They inhibit intestinal peristalsis, promoting bacterial overgrowth, severe paralytic ileus, toxic megacolon, systemic toxicity, central nervous system depression, and death.

Antimicrobial Therapy in Acute Gastroenteritis

Routine antibiotic administration in acute watery gastroenteritis is not recommended and is often harmful.

Shiga Toxin-producing E. coli (STEC): Antibiotic therapy is strictly contraindicated because bactericidal agents induce the bacterial SOS response, triggering massive lysis of bacteria and surge in systemic Shiga toxin release, substantially increasing the risk of Hemolytic Uremic Syndrome (HUS) .

Non-typhoidal Salmonella: Antibiotics prolong fecal shedding, induce asymptomatic carrier states, and increase relapse rates. Antibiotics (IV ceftriaxone or oral ciprofloxacin/azithromycin) are strictly reserved for infants under 3 months, immunocompromised hosts, sickle cell disease (risk of Salmonella osteomyelitis), or systemic bacteremic dissemination.

Specific Antibiotic Indications: Definitively indicated for culture-proven Shigella dysentery (azithromycin or ceftriaxone to reduce transmission and clinical duration), selected Campylobacter enteritis (especially dysentery, severe/high-risk disease or transmission control; azithromycin, with greatest benefit when started early), Vibrio cholerae , and severe Clostridioides difficile enterocolitis (oral vancomycin or fidaxomicin).

Micronutrient Supplementation and Probiotics

Zinc Supplementation: WHO 2024 suggests 5 mg/day for up to 14 days for children up to 10 years with acute watery or persistent diarrhoea. UNICEF July 2026 advises continued 20 mg/day for 14 days while 5-mg products are unavailable. Zinc can shorten diarrhoea, particularly in deficient populations; ESPGHAN does not recommend routine supplementation where zinc deficiency is rare.

Probiotics: Active strains with documented efficacy in ESPGHAN clinical practice guidelines include Lactobacillus rhamnosus GG and Saccharomyces boulardii . When administered early at doses ≥ 10 10 CFU/day \ge 10^{10}\text{ CFU/day} ≥ 1 0 10 CFU/day , they reduce the duration of viral diarrhea by approximately 24 hours.